The company manufactures pharmaceutical and edible grade gelatine, along with by-products like dicalcium phosphate and ossein, primarily serving the healthcare and capsule manufacturing industries.
The company operates in a commodity chemical space with no evidence of a moat; returns on capital are consistently below the cost of capital, and net margins are near zero or negative despite claims of being a critical supplier to the 'Pharmacy of the World.'
Capital is primarily trapped in low-return fixed assets and inventory; the company relies on unsecured loans from the Managing Director to sustain operations, and no dividends have been paid in recent years due to inadequate profits.
The company's collapse was driven by a lethal combination of extreme leverage and a total lack of pricing power in a commodity market. As interest rates rose and the Managing Director eventually ceased providing unsecured lifelines, the razor-thin margins were entirely consumed by debt service. The persistent inability to generate cash from operations led to a liquidity crisis, forcing a fire sale of fixed assets that were already yielding returns far below the cost of capital, ultimately wiping out equity holders as the business proved it was a 'charity' for lenders rather than a vehicle for owners.
RichFakir rates C J Gelatine Products Ltd's business quality as poor — 12/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, C J Gelatine Products Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on C J Gelatine Products Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of C J Gelatine Products Ltd's fair value is about ₹4 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →